Provided by Tiger Trade Technology Pte. Ltd.

Maze Therapeutics

26.43
-0.2200-0.83%
Post-market: 26.430.00000.00%19:30 EDT
Volume:633.05K
Turnover:16.89M
Market Cap:1.46B
PE:-10.50
High:27.49
Open:27.08
Low:26.36
Close:26.65
52wk High:53.65
52wk Low:21.95
Shares:55.25M
Float Shares:37.25M
Volume Ratio:0.81
T/O Rate:1.70%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.5172
EPS(LYR):-3.0510
ROE:-37.35%
ROA:-21.79%
PB:3.22
PE(LYR):-8.66

Loading ...

Maze Therapeutics Shareholders Elect Directors, Ratify Auditor

TIPRANKS
·
Jun 11

Maze Therapeutics shareholders elect Coloma, Kumar as directors at annual meeting

Reuters
·
Jun 11

Maze Therapeutics CEO Jason V. Coloma sells 6,643 shares worth $174,171.83

Reuters
·
Jun 04

Maze Therapeutics President, R&D and CMO Harold Bernstein disposes of common shares worth $381,499.47

Reuters
·
Jun 04

Maze Therapeutics posts corporate presentation on genetics-driven kidney, metabolic disease drug pipeline

Reuters
·
Jun 03

Maze Therapeutics CSBO Atul Dandekar disposes of 7,500 common shares for $197,554‬

Reuters
·
Jun 03

Maze Therapeutics CEO Jason V. Coloma disposes of 32,564 common shares worth $846,980.45

Reuters
·
May 28

Maze Therapeutics to Participate in Two Upcoming Investor Conferences

GlobeNewswire
·
May 27

J.P. Morgan Keeps Their Buy Rating on Maze Therapeutics, Inc. (MAZE)

TIPRANKS
·
May 23

Maze Therapeutics CFO Expands Role Amid Finance Leadership Change

TIPRANKS
·
May 23

Maze Therapeutics SVP Finance Amy Bachrodt resigns, effective June 1

Reuters
·
May 23

Maze CEO Jason Coloma disposes 1,938 Maze Therapeutics shares worth $50,388

Reuters
·
May 19

Maze Therapeutics President R&D, CMO Harold Bernstein sells common shares worth $393,354

Reuters
·
May 19

LifeSci Capital Remains a Buy on Maze Therapeutics, Inc. (MAZE)

TIPRANKS
·
May 16

Analysts Offer Insights on Healthcare Companies: Shoulder Innovations, Inc. (SI), Maze Therapeutics, Inc. (MAZE) and PACS Group Inc (PACS)

TIPRANKS
·
May 14

Maze Therapeutics (MAZE) Q1 Loss Of US$24.2 Million Reinforces Bearish Earnings Narratives

Simply Wall St.
·
May 14

Wedbush Sticks to Their Buy Rating for Maze Therapeutics, Inc. (MAZE)

TIPRANKS
·
May 13

Maze Therapeutics: Buy Rating Reiterated, $57 Price Target Maintained on Strong Balance Sheet and Advancing Kidney Disease Pipeline

TIPRANKS
·
May 13

J.P. Morgan Remains a Buy on Maze Therapeutics, Inc. (MAZE)

TIPRANKS
·
May 13

Analysts Offer Insights on Healthcare Companies: Kura Oncology (KURA) and Maze Therapeutics, Inc. (MAZE)

TIPRANKS
·
May 13